- A totally new malaria cure, based on an Asian medicinal herb, is to be presented at a congress in Yaoundé, Cameroon, on Monday and to the African market in 2006. The medicine, costing just 1 euro per adult patient and 50 cent per child, is described as "a tremendous breakthrough that could save millions of lives," by its producers.
The new malaria cure was today made public by Dafra Pharma, a Belgian company specialised on malaria medicines since 1997. The "new single-day cure for malaria" has already been widely tested on several locations in Africa, making it ready for marketing in 2006.
The efficacy of the new treatment was tested by Professor Penali from the Pasteur Institute in Abidjan (Côte d'Ivoire) in accordance with World Health Organisation (WHO) regulations, Dafra informs. "After the initial cure, which takes just a day, patients suffered no subsequent relapses, not even 28 days after the start of treatment, nor were any parasites left in the patients' blood," the company says in a statement.
In addition to this study in Côte d'Ivoire, the Belgian pharmaceutical company had conducted several field studies testing the drug on human in Congo Kinshasa (DRC). Here, the findings had been "reconfirmed".
The company holds that its new cure is simpler, more effective and cheaper than any other malaria cures on the market. It is a fixed-dose combination (FDC) of two active ingredients in a single tablet. "Mounting resistance to existing treatments and problems associated with post-treatment relapses have rendered more conventional therapies increasingly ineffective," Dafra says in its statement.
The company had developed three different FDC's for patients of different weights, including one for children, infants or pregnant women. In Africa, in particular children are very affected by malaria, causing very high mortality rates.
The new cure has been developed with a special mind for the African market. According to the company, "the recommended price for government purchases of the drug will be just 1 euro per adult patient and 50 cent per child, making the new one-day therapy the cheapest anti-malarial treatment of all Artemisinin based Combination Therapies (ACT's)."
Dafra Pharma plans to unveil its new medicine on 14 November at the Multilateral Initiative for Malaria (MIM) Congress in Yaoundé, which some 2,000 scientists will attend. The new treatment "will be launched on the African market in 2006," the company adds.
The Belgian company is already present all over the African market with other anti-malaria drugs based on the same extract from an Asian herb - artémisinine. Dafra Pharma has subsidiaries in Mali, South Africa and Kenya where it also produces generic drugs. It exports to more than 40 countries world-wide and has more than 115 employees working in Africa.
afrol News - It is called "financial inclusion", and it is a key government policy in Rwanda. The goal is that, by 2020, 90 percent of the population is to have and actively use bank accounts. And in only four years, financial inclusion has doubled in Rwanda.
afrol News - The UN's humanitarian agencies now warn about a devastating famine in Sudan and especially in South Sudan, where the situation is said to be "imploding". Relief officials are appealing to donors to urgently fund life-saving activities in the two countries.
afrol News - Fear is spreading all over West Africa after the health ministry in Guinea confirmed the first Ebola outbreak in this part of Africa. According to official numbers, at least 86 are infected and 59 are dead as a result of this very contagious disease.
afrol News - It is already a crime being homosexual in Ethiopia, but parliament is now making sure the anti-gay laws will be applied in practical life. No pardoning of gays will be allowed in future, but activist fear this only is a signal of further repression being prepared.
afrol News / Africa Renewal - Ethiopia's ambitious plan to build a US$ 4.2 billion dam in the Benishangul-Gumuz region, 40 km from its border with Sudan, is expected to provide 6,000 megawatts of electricity, enough for its population plus some excess it can sell to neighbouring countries.